Trial · NCT07538193
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
NCT07538193, Not applicable, Not yet recruiting, Tang-Du Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer. Trials, record NCT07538193. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07538193
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
- NCT number
- NCT07538193
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 28 participants, estimated
- Lead sponsor
- Tang-Du Hospital
- Conditions
- Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging, Lymphatic Metastasis
- Interventions
- Iparomlimab and Tuvonralimab combined with Platinum-Based Chemotherapy (Pemetrexed/Carboplatin for Non-squamous; Nab-paclitaxel/Carboplatin for Squamous)
- First posted
- 2026-04-20
- Last updated
- 2026-04-20
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological Complete Response (pCR) rate | At the time of surgery, approximately 9-15 weeks after enrollment | The percentage of subjects with no residual viable tumor cells in the resected primary tumor bed and lymph nodes after lung cancer resection. |
| Secondary | Major Pathological Response (MPR) rate | At the time of surgery, approximately 9-15 weeks after enrollment | The percentage of subjects with ≤10% residual viable tumor cells in the resected primary tumor bed and lymph nodes after lung cancer resection. |
| Secondary | Objective Response Rate (ORR) | From enrollment to pre-surgery assessment, approximately 9-15 weeks | The proportion of subjects achieving complete response (CR) or partial response (PR) on imaging according to RECIST v1.1 criteria prior to surgery. |
| Secondary | R0 Resection Rate | At the time of surgery | The percentage of subjects undergoing lung cancer resection who achieve complete resection with negative margins. |
| Secondary | Event-Free Survival (EFS) | From enrollment to up to 2 years post-surgery | Defined as the time from first study drug administration to the occurrence of disease progression precluding surgery, local or distant recurrence, or death from any cause. |
| Secondary | Overall Survival (OS) | From enrollment to up to 2 years post-surgery or death | Defined as the time from first study drug administration to death from any cause. |
| Secondary | Safety and Tolerability | From first dose to 90 days after last dose | Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI-CTCAE v5.0; rates of dose interruptions, modifications, and discontinuations due to AEs. |
| Secondary | Rate of Delayed or Cancelled Surgery | From completion of neoadjuvant therapy to scheduled surgery date, approximately 6 weeks | The percentage of subjects whose planned surgery is delayed beyond the protocol-specified window or cancelled. |
| Secondary | Surgery Duration | At the time of surgery | The total time from surgical incision to closure, measured in minutes. |
| Secondary | Hospitalization Duration | From surgery date to hospital discharge, approximately 1-4 weeks | The total number of days from surgery to hospital discharge. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07538193
GET https://conductscience.org/api/trials/v1/NCT07538193/registered